

**TOP
10**

**Journal of
Thoracic
Oncology**

**Most Cited
JTO Articles
Published in
2025**

180 Citations



**Durvalumab
With or Without
Tremelimumab in
Combination With
Chemotherapy in
First-Line Metastatic NSCLC:
Five-Year Overall Survival
Outcomes From the
Phase 3 POSEIDON
Trial**

**Peters S,
Cho BC,
Luft AV,
et al.**

28 Citations

**Chen H,
Yang S,
Wang L,
et al.**

**High-Dose
Furmonertinib in
Patients With EGFR-
Mutated NSCLC and
Leptomeningeal
Metastases: A
Prospective Real-
World Study**

23 Citations

**Dowlati A,
Chiang AC,
Cervantes A,
et al.**

**Phase 2
Open-Label
Study of Sacituzumab
Govitecan as Second-Line
Therapy in Patients With
Extensive-Stage SCLC:
Results From
TROPiCS-03**

20 Citations

**Risk Factors for
Locoregional Relapse
After Segmentectomy:
Supplementary Analysis
of the JCOG0802/
WJOG4607L Trial**

**Nakagawa K,
Watanabe SI,
Wakabayashi M,
et al.**

20 Citations

**Chou TY,
Dacic S,
Wistuba I,
et al.**

**Differentiating
Separate Primary
Lung Adenocarcinomas
From Intrapulmonary
Metastases With Emphasis
on Pathological and
Molecular Considerations:
Recommendations From the
International Association
for the Study of Lung
Cancer Pathology
Committee**

19 Citations

**Phase II
Randomized
Study of Maintenance
Atezolizumab Versus
Atezolizumab Plus
Talazoparib
in Patients With SLFN11
Positive Extensive-Stage
SCLC: S1929**

**Karim NA,
Miao J,
Reckamp,
et al.**

18 Citations

**Marinelli D,
Nuccio A,
Federico AD,
et al.**

**Improved
Event-Free
Survival After Complete
or Major Pathologic
Response in Patients
With Resectable NSCLC
Treated With Neoadjuvant
Chemoimmunotherapy
Regardless of Adjuvant
Treatment: A Systematic
Review and Individual
Patient Data Meta-
Analysis**

18 Citations

**Final Overall
Survival and
Long-Term Safety of
Lorlatinib in Patients
With ALK-Positive NSCLC
From the Pivotal Phase
2 Study: A Brief
Report**

**Ou SI,
Solomon BJ,
Besse B,
et al.**

15 Citations

**Besse B,
Goto K,
Wang Y,
et al.**

**Amivantamab
Plus Lazertinib
in Patients With
EGFR-Mutant NSCLC
After Progression on
Osimertinib and Platinum-
Based Chemotherapy:
Results From
CHRYSLIS-2
Cohort A**

14 Citations